Cover Image

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Background: The synergistic effects of antiangiogenic inhibitor bevacizumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) therapy were encouraging in patients with EGFR-mutant advanced NSCLC, though some controversy remains. The specific subgroup of patients who might be...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haosheng Zheng (Author), Xianyu Qin (Author), Yuzhen Zheng (Author), Xingping Yang (Author), Jian Tan (Author), Weijie Cai (Author), Shiyun He (Author), Hongying Liao (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis
by: Haosheng Zheng, et al.
Published: (2024)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015)

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
by: Weijie Ma, et al.
Published: (2021)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024)

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
by: Yi-Nan Liu, et al.
Published: (2020)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
by: Xiaoying Hou, et al.
Published: (2018)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
by: Jianling Bi, et al.
Published: (2021)

4-Aryl-N-phenylpyrimidin-2-amines targeting EGFR-tyrosine kinase attenuated EGFR-expressing cell lines
by: Lueacha Tabtimmai, et al.
Published: (2022)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
by: Xiaohan Zhou, et al.
Published: (2020)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
by: Cornelius Hempel, et al.
Published: (2017)

EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
by: Fabio Villa
Published: (2015)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
by: Wei-Yun Lai, et al.
Published: (2014)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
by: Chien C-R, et al.
Published: (2012)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
by: Tim Fischer, et al.
Published: (2018)

Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy
by: Priyanka S. Waghmare, et al.
Published: (2024)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
by: Desh Deepak Singh, et al.
Published: (2022)

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
by: Shao J, et al.
Published: (2024)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
by: Haiyan Xu, et al.
Published: (2022)

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
by: Ou SH, et al.
Published: (2015)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
by: Gerald HJ Mickisch, et al.
Published: (2011)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
by: Marialucia Iacovino, et al.
Published: (2020)

Tyrosine kinases in rheumatoid arthritis
by: Kobayashi Akiko, et al.
Published: (2011)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
by: Xiaotong Song, et al.
Published: (2023)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)